Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27139 | 0.91 | RECQL (0.32) | CHRM2CHRM1CHRM3 | |
| SCHEMBL30968097 | 0.91 | POLB (0.35) | — | |
| Ammonia Solution, Strong SCHEMBL18049530 | 0.89 | POLB (0.34) | — | |
| SCHEMBL931097 | 0.88 | RECQL (0.33) | CHRM2CHRM1CHRM3 | |
| SCHEMBL24899993 | 0.81 | VNN1 (0.33) | — | |
| SCHEMBL1164859 | 0.81 | CHRM2 (0.52) | CHRM2CHRM1CHRM3TDP1 | |
| SCHEMBL1164966 | 0.81 | CHRM2 (0.52) | CHRM2CHRM1CHRM3TDP1 | |
| SCHEMBL17062522 | 0.81 | CHRM2 (0.52) | CHRM2CHRM1CHRM3TDP1 | |
| SCHEMBL21808534 | 0.81 | CHRNB2 (0.34) | NOTUM | |
| SCHEMBL19617523 | 0.81 | CHRM2 (0.52) | CHRM2CHRM1CHRM3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4496626-A1 | HYDROXYMETHYL AZABICYCLO[2.2.1]HEPTANES AND MEDICAL USES THEREOF | Atrogi AB (SE) | 2025-01-29 | — | — | EP | disclosed |
| CN-119053595-A | Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors | 尼坎治疗公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-111491938-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230365572-A1 | HYDROXYLBENZYL AZABICYCLO[2.2.1]HEPTAN-1-ANE DRIVATIVES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023180472-A1 | HYDROXYMETHYL AZABICYCLO[2.2.1]HEPTANES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2023-09-28 | — | — | WO | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2391628-A1 | 2-AZA-BICYCLOÝ2.2.1¨HEPTANE COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010087762-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
| EP-1572205-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CHRM2 4725/4885CHRM1 4823/4885CHRM3 4812/4885 |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | CHRM2 4725/4885CHRM1 4823/4885CHRM3 4812/4885 |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | CHRM2 4816/4885CHRM1 4866/4885CHRM3 4862/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CHRM2 4725/4885CHRM1 4823/4885CHRM3 4812/4885 |
| US-20230365572-A1 | HYDROXYLBENZYL AZABICYCLO[2.2.1]HEPTAN-1-ANE DRIVATIVES AND MEDICAL USES THEREOF | CYP1B1, CYP11B1, CYP11B2 | CHRM2 1554/4885CHRM1 748/4885CHRM3 2571/4885 |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | CHRM2 4725/4885CHRM1 4823/4885CHRM3 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.